September 29, 2007 -- Consolidation in China biotech was a major theme last week. China Resources (Holdings) will acquire Sanjiu Enterprises (including Sanjiu Medical & Pharmaceutical), Simcere bought a 51% stake in rival Boda Pharmaceutical, Beijing Med-Pharm scooped up the 51% of Sunstone Pharma it had not already agreed to buy, and the Russian CRO Synergy Research Group is on the lookout for a CRO partner in China. According to rumor, the SFDA will decrease IND approval to a short four months, and the FDA will soon accept all-China trials for drugs. Immtech was given Fast Track Status for pafuramidine, and Benda announced record orders for Gendicine®. More details...
